Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Treasury Shares (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Treasury Shares for 12 consecutive years, with $33.2 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 58.03% to $33.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.2 million through Dec 2025, up 58.03% year-over-year, with the annual reading at $33.2 million for FY2025, 58.03% up from the prior year.
  • Treasury Shares hit $621296.0 in Q4 2025 for Ani Pharmaceuticals, up from $613972.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.5 million in Q4 2024 to a low of $83000.0 in Q3 2021.
  • Historically, Treasury Shares has averaged $562063.4 across 5 years, with a median of $508500.0 in 2024.
  • Biggest five-year swings in Treasury Shares: crashed 50.0% in 2021 and later soared 256.82% in 2025.
  • Year by year, Treasury Shares stood at $3.1 million in 2021, then soared by 62.49% to $5.1 million in 2022, then skyrocketed by 97.9% to $10.1 million in 2023, then surged by 108.71% to $21.0 million in 2024, then soared by 58.03% to $33.2 million in 2025.
  • Business Quant data shows Treasury Shares for ANIP at $33.2 million in Q4 2025, $32.6 million in Q3 2025, and $31.6 million in Q2 2025.